Biodesix Sinks 29% After Q3 Revenue Miss, 2026 Guidance Cut to $101M-$103M
BDSX has more than doubled off its 52-week low of $5.26.
Summary
Biodesix shares dropped 29.44% to $14 in after-hours trading after Q3 revenue of $24 million came in 12.4% below the $27.44 million analyst estimate. The company cut full-year 2026 revenue guidance to $101 million-$103 million from the prior $108 million-$114 million range, an 8.1% reduction at the midpoint. CEO Scott Hutton blamed fewer contributing sales reps than planned, heavier primary-care seasonality, and delayed Development Services projects, with some of that work now shifting into 2027. Diagnostic Testing revenue rose 16% to $23 million on 24% higher test volume, and gross margin held at 81%, but the top-line shortfall and softer outlook are what drove the selloff. The report follows the 8-K and 10-Q filed November 5th and comes days after Chief Commercial Officer Kieran O'Kane's November 2nd departure, adding to execution concerns.
At the time of this announcement, BDSX was trading at $11.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $5.26 to $31.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.